(12) United States Patent
`McKenna et al.
`
`(10) Patent No.:
`(45) Date of Patent:
`
`US 9,492,392 B2
`*Nov. 15, 2016
`
`USOO9492392B2
`
`(54)
`(71)
`
`(72)
`
`(73)
`
`(*)
`
`(21)
`(22)
`(65)
`
`(60)
`
`(60)
`
`(51)
`
`(52)
`
`TAMPER RESISTANT DOSAGE FORMS
`
`Applicant: Purdue Pharma L.P., Stamford, CT
`(US)
`Inventors: William H. McKenna, Yonkers, NY
`(US); Richard O. Mannion, Furlong,
`PA (US); Edward P. O'Donnell,
`Basking Ridge, NJ (US); Haiyong H.
`Huang, Princeton, NJ (US)
`Assignees: PURDUE PHARMA L.P., Stamford,
`CT (US); PURDUE
`PHARMACEUTICALS L.P., Wilson,
`NC (US)
`Subject to any disclaimer, the term of this
`patent is extended or adjusted under 35
`U.S.C. 154(b) by 0 days.
`This patent is Subject to a terminal dis
`claimer.
`
`Notice:
`
`Appl. No.: 14/729,634
`Filed:
`Jun. 3, 2015
`
`Prior Publication Data
`US 2015/0265599 A1
`Sep. 24, 2015
`
`Related U.S. Application Data
`Continuation of application No. 14/515,924, filed on
`Oct. 16, 2014, now Pat. No. 9,084,816, which is a
`continuation of application No. 13/803,132, filed on
`Mar. 14, 2013, now abandoned, which is a division of
`application No. 1 1/844,872, filed on Aug. 24, 2007,
`now Pat. No. 8,894,987.
`Provisional application No. 60/840,244, filed on Aug.
`25, 2006.
`
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`(2006.01)
`
`Int. C.
`A6 IK 3/485
`A6 IK 9/28
`A6 IK 47/10
`A6 IK 9/20
`A6 IK 9/16
`46.3/06
`A6 IK 9/00
`A6 IK 47/34
`A6 IK 9/24
`A6 IK 45/06
`46.3/10
`B29C 43/00
`U.S. C.
`CPC. A61K 9/28 (2013.01); A61J 3/06 (2013.01);
`A61J 3/10 (2013.01); A61K 9/0002 (2013.01);
`A61K 9/1641 (2013.01); A61K 9/209
`(2013.01); A61 K9/2013 (2013.01); A61 K
`9/2018 (2013.01); A61K 9/2031 (2013.01);
`A6IK 9/2054 (2013.01); A61K 9/2077
`(2013.01); A61 K9/2095 (2013.01); A61 K
`9/2853 (2013.01); A61K 9/2866 (2013.01);
`A61K 9/2893 (2013.01); A61K 31/485
`
`(2013.01); A61K 45/06 (2013.01); A61K 47/10
`(2013.01); A61K 47/34 (2013.01); B29C
`43/003 (2013.01); A61 K9/2072 (2013.01)
`(58) Field of Classification Search
`None
`See application file for complete search history.
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`636,438 A 11/1899 Lovejoy
`1468,805 A
`9, 1923 Freund
`1485,673 A
`3, 1924 Freund
`2,772,270 A 11, 1956 Weiss
`3,096,248 A
`7, 1963 Rudzki
`3,806,603 A
`4, 1974 Gaunt et al.
`3,885,027 A
`5, 1975 Shaw et al.
`3,941,865 A
`3, 1976 Miller et al.
`3,966,747 A
`6, 1976 Monkovic et al.
`3,980,766 A
`9, 1976 Shaw et al.
`4,070,494 A
`1/1978 Hoffmeister et al.
`4,175,119 A 11, 1979 Porter
`4.404,183 A
`9, 1983 Kawata et al.
`4,501,828 A
`2, 1985 Hadermann et al.
`4,599,342 A
`7/1986 LaHann
`4,612,008 A
`9/1986 Wong et al.
`4,616,644 A 10, 1986 Saferstein et al.
`4,619,988 A 10/1986 Leung et al.
`4,629,621 A 12/1986 Snipes
`4,629,624 A 12, 1986 Grouiller et al.
`4,690,822 A
`9, 1987 Uemura et al.
`4,713,243 A 12/1987 Schiraldi et al.
`4,744,976 A
`5/1988 Snipes et al.
`4,764,378 A
`8, 1988 Keith et al.
`4,765,989 A
`8/1988 Wong et al.
`4,774,074 A
`9/1988 Snipes
`4,783,337 A 11/1988 Wong et al.
`(Continued)
`FOREIGN PATENT DOCUMENTS
`
`CA
`CA
`
`10, 1981
`1110972 A1
`6, 2000
`2352874 A1
`(Continued)
`
`OTHER PUBLICATIONS
`
`Mai et al. (Materiaux et Constructions 1982. 15(2); pp. 99-106).*
`(Continued)
`
`Primary Examiner — Misook Yu
`Assistant Examiner — Kauser Akhoon
`(74) Attorney, Agent, or Firm — Troutman Sanders LLP
`
`ABSTRACT
`(57)
`The present invention relates to pharmaceutical dosage
`forms, for example to a tamper resistant dosage form includ
`ing an opioid analgesic, and processes of manufacture, uses,
`and methods of treatment thereof.
`
`29 Claims, 27 Drawing Sheets
`
`KASHIV1001
`IPR of Patent No. 9,492,392
`
`

`

`US 9,492,392 B2
`Page 2
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`2/1989 Snipes et al.
`4,806,337 A
`8/1989 Oshlack
`4,861,598 A
`10/1989 Schiraldi et al.
`RE33,093 E
`1/1990 Theeuwes et al.
`4,892,778 A
`4,960,814. A 10/1990 Wu et al.
`4970,075. A 11, 1990 OShlack
`5,004601 A
`4/1991 Snipes
`5,019,397 A
`5/1991 Wong et al.
`5,051.222 A
`9, 1991 Marten et al.
`5,139,790 A
`8/1992 Snipes
`5,169,645 A 12/1992 Shukla et al.
`5,200,197 A
`4/1993 Wright et al.
`5,211,892. A
`5, 1993 Gueret
`5,266,331 A 11/1993 Oshlack et al.
`5,273.758 A 12/1993 Royce
`5,273.760 A 12/1993 Oshlack et al.
`5286,493 A
`2f1994 OShlack et al.
`5.330,766 A
`7, 1994 Morella et al.
`535074 A
`9, 1994 Takada
`5,356.467 A 10, 1994 O'Shlack et al.
`5.378.474 A
`1/1995 Morella et al.
`5.393.528 A
`2, 1995 Staab
`5.405.366 A
`4/1995 Fox et al.
`5.458887. A
`10/1995 Chenet al.
`5,472712 A
`13/1995 Oshiacket al.
`5,478,577 A 12/1995 Sackler et al.
`5,508,042 A
`4, 1996 OShlack et al.
`5.549.912. A
`8, 1996 OShlack et al.
`5,580,578 A
`12, 1996 Oshiacket al.
`5,654.005 A
`8, 1997 Chen et al.
`5,656,395 A
`8, 1997 OShlack et al.
`5,672360 A
`9, 1997 Sackler et al.
`5,695,781 A 12/1997 Zhang et al.
`5.801.201 A
`9, 1998 Graudums et al.
`5,849.240 A 12/1998 Miller eral
`5,866,161 A
`2f1999 Childers et al.
`5,866,164 A
`2/1999 Kuczynski et al.
`5,886.164 A
`3, 1999 Bird et al.
`5,943. A
`6, 1999 Merrill et al.
`5.945.125 A
`8, 1999 Kim
`5.948,787 A
`9, 1999 Merrill et al.
`5 958,452 A
`9, 1999 OShlack et al.
`5958.459 A
`9, 1999 Chasin et al.
`5968,551 A
`10/1999 oshiacket al.
`6,008.355 A 12/1999 Huang et al.
`6,009,690 A
`1/2000 Rosenberg et al.
`6,096,339 A
`8/2000 Ayer et al.
`6,117.453 A
`9, 2000 Seth et al.
`6,177.567 B1
`1/2001 Chietal.
`6.328,863 Bi
`52001 Palermo et al.
`6,238,697 B1
`5/2001 Kumar et al.
`6.245,357 B1
`6/2001 Edgren et al.
`6,251,430 B1
`6/2001 Zhang et al.
`6,261,599 B1
`7/2001 Oshlack et al.
`6.262.266 B1
`7/2001 Chiu et al.
`6.277.409 Bi
`8/2001 Liber et al.
`6,306.438 B1
`10/2001 Oshacket al.
`6,309.668 B1
`10, 2001 Bastin et al.
`6 340.475 B2
`1/2002 Shell et al.
`6,357,957 B1
`3/2002 Champin
`6.375,957 B1
`4/2002 Kaiko et al.
`6.436,441 B1
`8/2002 Sako et al.
`6 461,644 B1
`10, 2002 Jackson et al.
`6,488962 B 13/2002 Bernereal.
`6,488.963 B1 12/2002 McGinity et al.
`6,491,683 B1
`12/2002 Dong et al.
`6,534,089 B1
`3/2003 Ayer et al.
`6,547.997 B1
`4/2003 Breitenbach et al.
`6,572,885 B2
`6, 2003 Oshlack et al.
`6,635,280 B2 10/2003. Shell et al.
`6,699,503 B1
`3, 2004 Sako et al.
`6,723,340 B2
`4/2004 Gusler et al.
`6,733,783 B2
`5, 2004 OShlack et al.
`6,864,370 B1
`3/2005 Lin et al.
`6,919,373 B1
`7/2005 Lam et al.
`
`8, 2005 Lam et al.
`6,930,129 B2
`7,129,248 B2 10/2006 Chapman et al.
`7,141,250 B2 11/2006 Oshlack et al.
`7,153,966 B2 12/2006 Casner et al.
`7,157,103 B2
`1/2007 Sackler
`7.201.920 B2
`4/2007 Kumar et al.
`7,399,488 B2
`7/2008 Hirsh et al.
`7,674,799 B2
`3/2010 Chapman et al.
`7,674,800 B2
`3/2010 Chapman et al.
`7,683,072 B2
`3/2010 Chapman et al.
`7,776,314 B2
`8/2010 Bartholomaus et al.
`7,842,307 B2 11/2010 Oshlack et al.
`8, 114,383 B2
`2/2012 Bartholomaus et al.
`8,163,798 B2
`4/2012 Gupta et al.
`8,309,060 B2 11/2012 Bartholomaus et al.
`8.337,888 B2 12/2012 Wright et al.
`8,808,741 B2
`8/2014 McKenna et al.
`8,815,289 B2
`8/2014 McKenna et al.
`8,821,929 B2
`9/2014 McKenna et al.
`8,834,925 B2
`9/2014 McKenna et al.
`8,846,086 B2
`9/2014 McKenna et al.
`8,894.987 B2 11/2014 McKenna et al.
`8,894.988 B2 11/2014 McKenna et al.
`8,911,719 B2 12/2014 McKenna et al.
`9,084,816 B2
`7/2015 McKenna et al.
`2001/0031278 A1 10, 2001 Oshlack et al.
`2001/003.6476 A1 11/2001 Oshlack et al.
`2001/0038852 A1
`11/2001 Kolter et al.
`2002/0051820 A1
`5, 2002. Shell et al.
`2002/01 14838 A1
`8/2002 Ayer et al.
`2002fO1871.92 A1 12/2002 Joshi et al.
`2002/0192277 A1 12/2002 Oshlack et al.
`2003,0004177 A1
`1/2003 Kao et al.
`2003, OO15814 A1
`1/2003 Krull et al.
`2003/0044464 A1
`3/2003 Ziegler et al.
`2003, OO64099 A1
`4/2003 Oshlack et al.
`2003, OO650O2 A1
`4/2003 Caruso et al.
`2003/0068375 A1 * 4/2003 Wright et al. ................ 424/468
`2003.0068392 A1
`4, 2003 Sackler
`2003/0069318 A1
`4/2003 Dang et al.
`2003/0091630 A1
`5/2003 Louie-Helmet al.
`2003/0092724 A1
`5/2003 Kao et al.
`2003/0104052 A1
`6/2003 Berner et al.
`2003. O104053 A1
`6/2003 Gusler et al.
`2003/01 18641 A1
`6/2003 Maloney et al.
`2003/O1241.85 A1
`7/2003 Oshlack et al.
`2003/0129234 A1
`7/2003 Baichwal et al.
`2003/0.133985 A1
`7/2003 Louie-Helm et al.
`2003. O152622 A1
`8, 2003 Louie-Helmet al.
`2003.0161882 A1
`8, 2003 Waterman
`2003/0203024 A1 10, 2003 Sako et al.
`2003,0224051 A1 12/2003 Fink et al.
`2003,0229158 A1 12/2003 Chen et al.
`2004/0010000 A1
`1/2004 Ayer et al.
`2004/0011806 A1
`1/2004 Luciano et al.
`2004/0024006 A1
`2/2004 Simon
`2004.?0047907 A1
`3/2004 OShlack et al.
`2004/O110781 A1
`6/2004 Harmon et al.
`2004/O126428 A1
`7/2004 Hughes et al.
`2004/O137156 A1
`7, 2004 Lee et al.
`2004/0156899 A1
`8/2004 Louie-Helm et al.
`2004/0170680 A1
`9, 2004 OShlack et al.
`2004/O185097 A1
`9/2004 Kannan et al.
`2004/0185105 A1
`9, 2004 Berner et al.
`2004/0213848 A1 10, 2004 Li et al.
`2004/0241234 A1 12, 2004 Vilkov
`2005/0031546 A1
`2/2005 Bartholomaus et al. .... 424/10.1
`2005/0106249 A1
`5/2005 Hwang et al.
`2005/O112O67 A1
`5/2005 Kumar et al.
`2005/O127555 A1
`6/2005 Gusik et al.
`2005. O152843 A1
`7/2005 Bartholomaus et al.
`2005/0222188 A1 10/2005 Chapman et al.
`2005/0236741 A1 10, 2005 Arkenau et al.
`2005/0266084 A1 12/2005 Li et al.
`2006,0002859 A1
`1/2006 Arkenau et al.
`2006,0002860 A1
`1/2006 Bartholomaus et al.
`2006/0173029 A1
`8/2006 Chapman et al.
`2006, O188447 A1
`8/2006 Arkenau-Maric et al.
`2006, O193914 A1
`8, 2006 Ashworth et al.
`
`KASHIV1001
`IPR of Patent No. 9,492,392
`
`

`

`US 9,492,392 B2
`Page 3
`
`(56)
`
`References Cited
`
`U.S. PATENT DOCUMENTS
`
`2006/0240.107 A1 10, 2006 Lenaerts et al.
`2006/02401 10 A1 10, 2006 Kiicket al.
`2006, O251724 A1 11, 2006 Farrell et al.
`2006/0269603 A1 11/2006 Brown Miller et al.
`2007/00036.16 A1
`1/2007 Arkenau-Maric et al.
`2007/0020335 A1
`1/2007 Chen et al.
`2007/0048228 A1
`3f2007 Arkenau-Maric et al.
`2007/0092573 A1
`4, 2007 Joshi et al.
`2007/0117826 A1
`5/2007 Janjikhel et al.
`2007/0117829 A1
`5/2007 Chapman et al.
`2007/0117831 A1
`5/2007 Chapman et al.
`2007/018.3979 A1
`8/2007 Arkenau-Maric et al.
`2007/0183980 A1
`8/2007 Arkenau-Maric et al.
`2007/0196396 A1
`8/2007 Pilgaonkar et al.
`2008/017.5908 A1
`7, 2008 Liu et al.
`2008/0248113 A1 10, 2008 Bartholomaus et al.
`2008/0274.183 A1 11, 2008 Cook
`2008/0317854 A1 12/2008 Arkenau et al.
`2009,0005408 A1
`1/2009 Arkenau-Maric et al.
`2009/0022798 A1
`1/2009 Rosenberg et al.
`2009/0081290 A1
`3f2009 McKenna et al.
`2010/0168148 A1
`7/2010 Wright et al.
`2011/003893.0 A1
`2/2011 Barnscheid et al.
`2013/025 1796 A1
`9, 2013 McKenna et al.
`2013/025 1797 A1
`9, 2013 McKenna et al.
`2013/025 1800 A1
`9, 2013 McKenna et al.
`2013/025 1801 A1
`9, 2013 McKenna et al.
`2013/0259938 A1 10, 2013 McKenna et al.
`2014/0024669 A1
`1/2014 McKenna et al.
`2014/003O327 A1
`1/2014 McKenna et al.
`2015, 0028512 A1
`1/2015 McKenna et al.
`2015 0037411 A1
`2/2015 McKenna et al.
`2015, 0037412 A1
`2/2015 McKenna et al.
`2015, 0037413 A1
`2/2015 McKenna et al.
`
`FOREIGN PATENT DOCUMENTS
`2S: A.
`539.
`2534932 A1
`2/2005
`2551231 A1
`T 2005
`2572491 A1
`1/2006
`689 109 AS 10/1998
`113O352 C
`12/2003
`1514721 A
`T 2004
`4309528 A1
`9, 1994
`19753534 A1
`6, 1999
`198OO698 A1
`T 1999
`19822979 A1 12/1999
`1985.5440 A1
`6, 2000
`10036400 A1
`6, 2002
`10227O77
`6, 2002
`6942.971O T2
`8, 2002
`10250O83 A1 12/2003
`10250O84 A1
`5.2004
`10336400 A1
`3f2005
`0008131 A1
`2/1980
`0.111144 A1
`6, 1984
`O1778.93 A2
`4, 1986
`0216453 A2
`4, 1987
`0226061 A2
`6, 1987
`O228417 A1
`T, 1987
`O232877 A2
`8, 1987
`O277289 A1
`8/1988
`O293,066 A2 11, 1988
`O328775 A1
`8/1989
`O583726 A2
`2?1994
`0598.606 A1
`5.1994
`O647448 A1
`4, 1995
`O661045 A1
`7, 1995
`O682945 A2 11/1995
`O693475 A1
`1, 1996
`O696598 A1
`2/1996
`O78O369 A1
`6, 1997
`O820698 A1
`1/1998
`
`A
`CA
`CA
`CA
`CH
`CN
`CN
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`DE
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`EP
`
`1, 1999
`O889045 A1
`EP
`1/2000
`O974343 A1
`EP
`2, 2000
`O98O894 A1
`EP
`5.2000
`O998.271 A1
`EP
`1250.045 A2 10, 2002
`EP
`12931.27 A2
`3, 2003
`EP
`1658055 A1
`5/2006
`EP
`1859789 A1 11, 2007
`EP
`1897545 A1
`3f2008
`EP
`2070538 A1
`6, 2009
`EP
`2080514 A1
`T 2009
`EP
`2O82742 A1
`T 2009
`EP
`2292229 A1
`3, 2011
`EP
`2292230 A1
`3, 2011
`EP
`2311459 A1
`4, 2011
`EP
`2343071 A1
`T, 2011
`EP
`2384754 A1
`11, 2011
`EP
`2399.579 A1 12, 2011
`EP
`239958.0 A1
`12/2011
`EP
`2450691 A
`1, 2009
`GB
`WO-9003776 A1
`4f1990
`WO
`WO-910795.0 A1
`6, 1991
`WO
`WO-9306723 A1
`4f1993
`WO
`WO-93.10758 A1
`6, 1993
`WO
`WO-9311749 A1
`6, 1993
`WO
`WO-94.06414 A1
`3, 1994
`WO
`WO-9408567 A1
`4f1994
`WO
`WO-9514460 A1
`6, 1995
`WO
`WO-95.20947 A1
`8/1995
`WO
`WO-9522319 A1
`8/1995
`WO
`WO-953O422 A1 11, 1995
`WO
`WO-96OOO66 A1
`1, 1996
`WO
`WO-9608253 A1
`3, 1996
`WO
`WO-96.14058 A1
`5, 1996
`WO
`WO-9632097 A1 10, 1996
`WO
`WO-9733566 A2
`9, 1997
`WO
`WO-9737689 A2 10, 1997
`WO
`WO-9749.384 A1 12, 1997
`WO
`WO-9749385 A1 12, 1997
`WO
`WO-982O073 A2
`5, 1998
`WO
`WO-984.4911 A1 10, 1998
`WO
`WO-9856.354 A2 12, 1998
`WO
`WO-9856.359 A2 12, 1998
`WO
`WO-992O255 A1
`4f1999
`WO
`WO-99321.19 A1
`T 1999
`WO
`WO-9932 120 A1
`T 1999
`WO
`WO-9944591 A1
`9, 1999
`WO
`WO-OOO9639 A2
`2/2000
`WO
`WO-0032166 A2
`6, 2000
`WO
`WO-0033835 A1
`6, 2000
`WO
`WO-O 115667 A1
`3f2001
`WO
`WO-O 145644 A2
`6, 2001
`WO
`WO-0226928 A1
`4, 2002
`WO
`WO-O2O87512 A2 11/2002
`WO
`WO-03 013476 A1
`2/2003
`WO
`WO-O3O13479 A1
`2/2003
`WO
`WO-O3O15531 A2
`2/2003
`WO
`WO-03024429 A1
`3f2003
`WO
`WO-03024430 A1
`3f2003
`WO
`WO-03026624 A1
`4, 2003
`WO
`WO-03028620 A1
`4, 2003
`WO
`WO-03028698 A2
`4? 2003
`WO
`WO-O3O35O29 A1
`5/2003
`WO
`WO-O3O35053 A1
`5/2003
`WO
`WO-O3O35054 A1
`5/2003
`WO
`WO-O3O35177 A2
`5, 2003
`WO
`WO-03053417 A2
`7, 2003
`WO
`WO-03072086 A1
`9, 2003
`WO
`WO-03094812 A1 11, 2003
`WO
`WO-03105808 A1 12/2003
`WO
`WO WO-2004O16618 A1
`2/2004
`WO WO-2004O26262 A2
`4, 2004
`WO WO-2004O26263 A2
`4, 2004
`WO WO-2004037230 A1
`5, 2004
`WO WO-2004O37259 A1
`5, 2004
`WO WO-2004037260 A1
`5, 2004
`WO WO-2004O93819 A2 11/2004
`WO
`2005.000310 A1
`1/2005
`WO WO-2005O16303 A2
`2/2005
`
`KASHIV1001
`IPR of Patent No. 9,492,392
`
`

`

`US 9,492,392 B2
`Page 4
`
`(56)
`
`References Cited
`
`FOREIGN PATENT DOCUMENTS
`
`2, 2005
`WO WO-2005O16313 A1
`2, 2005
`WO WO-2005O16314 A1
`5, 2005
`WO WO-2005041968 A2
`7/2005
`WO WO-2005063214 A1
`9, 2005
`WO WO-2005079760 A1
`WO WO-20050978O1 A1 10/2005
`WO WO-2005102286 A1
`11 2005
`WO WO-20060O2883 A1
`1, 2006
`WO WO-20060O2884 A1
`1, 2006
`WO WO-20060O2886 A1
`1, 2006
`WO
`2006O79550 A2
`8, 2006
`WO WO-2006082097 A1
`8, 2006
`WO WO-2006082099 A1
`8, 2006
`WO WO-2006084211 A2
`8, 2006
`WO WO-2007OO8752 A2
`1, 2007
`WO WO-2007048233 A1
`5/2007
`WO WO-2007053698 A2
`5/2007
`WO WO-2008O86804 A2
`T 2008
`WO WO-2009114648 A1
`9, 2009
`
`OTHER PUBLICATIONS
`
`AlKhatib et al. (AAPS PharmSciTech, 2010. 11(1); pp. 253-266).*
`Mpofu et al. (Journal of Colloid and Interface Science. 2004, 271;
`pp. 145-156).*
`Remington, 20th Edition, 2003, “Oral Solid Dosage Forms”.
`Remington, 20th Edition, 2003, “Sustained and Controlled-Release
`Drug Delivery Systems”.
`Gissinger et al. A comparative evaluation of the properties of some
`tablet disintegrants, Drug Development and Industrial Pharmacy
`6(5): 511-536. 1980.
`Porter et al. Process Optimization Using Design of Experiments,
`Pharmaceutical Technology: 1-7. (1997).
`Cunningham et al., "Coating Moisture-Sensitive Products', reprint
`of SAFyBI poster presentation, Buenos aires, Sep. 2005. Retrieved
`from:
`<<https://www.colorcon.com/literature/marketing/fc/
`Opadry'.620II/ads opadry II coat moist.pdf>>, last accessed
`Dec. 10, 2015.
`JB.. Ashworth, et al., “Effect of Tablet mechanical Stability on Drug
`Preference and Relative Street Value of Oxycodone Controlled
`Release (CR) Tablets in Experienced Oxycodone CR Abusers'
`(Abstract) Presented at the 69th Annual Scientific Meeting of the
`College on Problems of Drug Dependence (Quebec City, Canada,
`Jun. 16, 2007).
`J. Bartholomaeus, et al. “A New Technology to Increase the
`Mechanical Stability of Matrix Tablets to Prevent Abuse by Crush
`ing or Chewing” (Abstract) Presented at the Drug Formulations and
`Abuse Liability Conference "Impact of Drug Formulation on Abuse
`Liability, Safety and Regulatory Decisions” (North Bethesda, Mary
`land, Apr. 19-20, 2005), pp. 12-13.
`V.K. Thoma et al., “Bestimmung der In-vitro-Freigabe von Schwach
`basischen Wirkstoffen aus Retardarzneiformen.' Pharm. Ind. 51, Nr.
`3 (1989).
`S. Janicki et al., "Slow-Release Microballs: Method of Preparation.”
`Acta Pharm. Technol. 33(3) 154-155 (1987).
`R. Mank et al., “Darstellung wirkstoffhaltiger Extrusionsformlinge
`auf der Basis von Thermoplasten.” Pharmazie 45 (1990), H. 8; pp.
`592-593.
`R. Mank et al., “Darstellung wirkstoffhaltiger Extrusionsformlinge
`auf der Basis von Thermoplasten.” Pharmazie 44 (1989) H. 11; pp.
`773-776.
`P. Shivanand et al., “Factors Affecting Release of KCI from Melt
`Extruded Polyethylene Disks.” Pharmaceutical Research, Official
`Journal of the American Association of Pharmaceutical Scientists;
`Oct. 1991, vol. 8, No. 10.
`L. Yang et al., “Characterization of Compressibility and Compat
`ibility of Poly(ethylene oxide) Polymers for Modified Release
`Application by Compaction Simulator,” Journal of Pharmaceutical
`Sciences, vol. 85, No. 10, Oct. 1996.
`
`F. Zhang et al., “Properties of Sustained-Release Tablets Prepared
`by Hot-Melt Extrusion.” Pharmaceutical Development and Tech
`nology, 4(2), 241-250 (1999) pp. 241-250.
`A. Apicella et al., “Poly(ethylene oxide) (PEO) and different
`molecular weight PEO blends monolithic devices for drug release.”
`Biomaterials 1993, vol. 14, No. 2, pp. 83-90.
`M.M. Crowley et al., "Stability of polyethylene oxide in matrix
`tablets prepared by hot-melt extrusion.” Biomaterials 23 (2002)
`4241-4248.
`M. Efentakis et al., “Evaluation of High Molecular Weight
`Poly(Oxyethylene) (Polyox) Polymer: Studies of Flow Properties
`and Release Rates of Furosemide and Captopril from Controlled
`Release Hard Gelatin Capsules.” Pharmaceutical Development
`andTechnology, 5(3), 339-346 (2000).
`N. Follonier et al., “Various ways of modulating the release of
`diltiazem hydrochloride from hot-melt extruded sustained release
`pellets prepared using polymeric materials,” Journal of Controlled
`Release 36 (1995) 243-250.
`N.B. Graham, “Poly(Ethylene Glycol) Gels and Drug Delivery.”
`Poly(Ethylene Glycol) Chemistry: Biotechnical and Biomedical
`Applications, Chapter 17, 1992.
`C. D. Hanning et al., “The Morphine Hydrogel Suppository.” British
`Journal of Anaesthesia, 1988, 61, 221-227.
`Kim et al., “Preparation and Evaluation of Eudragit Gels V. Rectal
`Gel Preparations for Sustained Release and Avoidance of First-Pass
`Metabolism of Lidocaine.” Chem. Pharm. Bull, 40(10) 2800-2804
`(1992).
`Cherng-Ju Kim, “Drug Release from Compressed Hydrophilic
`POLYOX-WSR Tablets,’ Journal of Pharmaceutical Sciences, vol.
`84, No. 3, Mar. 1995.
`S.L. Madorsky et al., “Thermal Degradation of Polyethylene Oxide
`and Polypropylene Oxide,” Journal of Polymer Science, vol.
`XXXVI, pp. 183-194 (1959).
`A. Moroni et
`al.,
`“Application of Poly(Oxyethylene)
`Homopolymers in Sustained Release Solid Formulations.” Drug
`Development and Industrial Pharmacy, 21 (12), 141 1-1428 (1995).
`N. Ohnishi et al., “Effect of the Molecular Weight of Polyethylene
`Glycol on the Bioavailability of Indomethacin Sustained-Release
`Suppositories Prepared with Solid Dispersions.” Chem. Pharm.
`Bull, 35 (8) 351 1-3515 (1987).
`T. Ozeki et al., "Control of medicine release from solid dispersion
`composed of the poly(ethylene oxide)-carboxyvinylpolymer
`interpolymer complex by varying molecular weight of poly(ethyl
`ene oxide),” Journal of Controlled Release 58 (1999) 87-95.
`Pharmaceutical Research, Official Journal of the American Asso
`ciation of Pharmaceutical Scientists, Sep. 1989 (Supplement), vol.
`6, No. 9, 6.S-98.
`Pharmaceutical Research, Official Journal of the American Asso
`ciation of Pharmaceutical Scientists, Oct. 1991 (Supplement), Vo. 8,
`No. 10, 8. S-192.
`W. Prapaitrakul et al., “Release of Chlorpheniramine Maleate from
`Fatty Acid Ester Matrix Disks Prepared by Melt-extrusion.” J.
`Pharm. Pharmacol. 1991, 43: 377-381.
`J. Scheirs et al., “Characterizing the solid-state thermal oxidation of
`poly(ethylene oxide) powder.” Polymer, 1991, vol. 32, No. 11.
`O.L. Sprockel et al., “Permeability of Cellolose Polymers: Water
`Vapour Transmission Rates,” J. Pharm. Pharmacol. 1990, 42: 152
`157.
`J.L. Stringer et al., “Diffusion of Small molecular weight drugs in
`radiation-crosslinked poly(ethylene oxide) hydrogels,” Journal of
`Controlled Release 42 (1996) 195-202.
`E. G. Rippie et al., “Regulation of Dissolution Rate by Pellet
`Geometry,” Journal of Pharmaceutical Sciences, Vo. 58, No. 4, Apr.
`1969, pp. 428-431.
`Remington's Pharmaceutical Sciences 17th ed., Mack Publishing
`Co., (1985) 1418.
`M.S. Mesiha et al., “A Screening Study of Lubricants in Wet Powder
`Masses Suitable for Extrusion-Spheronization.” Drug Development
`and Industrial Pharmacy, 19(8), 943–959 (1993).
`N. Follonier et al., “Evaluation of Hot-Melt Extrusion as a New
`Technique for the Production of Polymer-Based Pellets for Sus
`
`KASHIV1001
`IPR of Patent No. 9,492,392
`
`

`

`US 9,492,392 B2
`Page 5
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`tained Release Capsules Containing High Loadings of Freely
`Soluble Drugs.” Drug Development and Industrial Pharmacy,
`20(8), 1323-1339 (1994).
`“2.9.8. Resistance to Crushing of Tablets.” Pharmaceutical Techni
`cal Procedures, European Pharmacopoeia, p. 135 (1997).
`Bauer et al., Coated Pharmaceutical Dosage Forms: Fundamentals,
`Manufacturing Techniques, Biopharmaceutical Aspects, Test Meth
`ods and Raw Materials, Scientific Publishers Stuttgart 1998, CRC
`Press, 8 pp.
`Commonwealth of Australia, In the matter of Australian Patent
`Application No. 2002305559 in the name of Endo Pharmaceuticals,
`Inc. and Opposition thereto by Mundipharma Pty Limited, apmm
`AO 111098466v3 206030879 1.10., pp. 1-4, 2008.
`Coppens et al., “Hypromellose, Ethylcellulose, and Polyethylene
`Oxide Use in Hot Melt Extrusion.” Pharmaceutical Technology, 5
`pp. (2005/2006).
`Huang, Hugh, Poster and Abstract on extruded POLYOX tablets
`presented at the poster session of 2000 AAPS Annual Meeting, 4 pp.
`Maggi et al., “Dissolution behaviour of hydrophilic matrix tablets
`containing two different polyethylene oxides (PEOs) for the con
`trolled release of a water-soluble drug. Dimensionality study.”
`Biomaterials, vol. 23, pp. 1113-1119 (2002).
`Proeschel et al., “Task-dependence of Activity/Bite-force Relations
`and its Impact on Estimation of Chewing Force from EMG, J Dent
`Res, vol. 81, No. 7, pp. 464-468 (2002).
`Schroeder et al., “Granulierung hydrophober Wirkstoffe im
`Planetwalzenextruder' (Summary in English), Wissenschaft and
`Technik, Pharm. Ind., vol. 65, No. 4, 367-372 (2003).
`“Oral Solid Dosage Forms,” Remington's Pharmaceutical Sciences,
`18th edition, Chapter 89, pp. 1633-1665 (1990).
`Chiao et al., “Sustained-Release Drug Delivery Systems.”
`Remington: The Science and Practice of Pharmacy, Chapter 94.
`Alfonso R. Gennaro, Ed., pp. 1660-1675 (1995).
`EP1014941: Opposition brief filed by opponent Grunenthal dated
`Dec. 23, 2009 (includes English-language translation) (24 pages).
`EP1658.054: Affidavit by Inventor of EP1658.054, Prof. Johannes
`Bartholomaus, dated Oct. 7, 2009, with English translation (28
`pages).
`EP1658054: Annex to Third party observation Test Report by
`Professor McGinity dated Jan. 26, 2009 (4 pages).
`EP1658054: English translation of Patentee's response dated Jan.
`15, 2009 (Reference C7) (8 pages).
`EP1658.054: Opposition brief filed on Mar. 27, 2008 (15 pages).
`EP1658.054: Patentee’s Response to Opposition dated Jan. 15, 2009
`(12 pages).
`EP1658054: Third party observation dated Feb. 2, 2009 (4 pages).
`EP1658.054: Third party observation dated Mar. 27, 2009 (3 pages).
`EP1658.054: Wolfgang, Ritschel, Die Tablette: Handbuch der
`Entwicklung, Herstellung and Qualitatssicherung (extract), with
`English translation (2002) (5 pages).
`EP1658055: Annex to Third Party Observation Test Report by
`Prof. McGinity dated Jan. 26, 2009 (4 pages).
`EP1658055: Berger et al., Water-Soluble Resins, pp. 169-201
`(1962) (34 pages).
`EP1658055: Ethylene Oxide Polymers, Union Carbide Corporation,
`Technical Booklet (reprinted from Encyclopedia of Polymer Sci
`ence and Technology, vol. 6, pp. 103-145 (1967).
`EP1658055: European Pharmacopoeia, 3rd Ed., chapter 2.9.8, 3
`pages (1997).
`EP1658055: Excerpt from Purdue Laboratory notebook (calibrated
`Instron test results) (4 pages)—Mar. 12, 2008.
`EP1658055: Experimental Report Breaking strength tests on cali
`brated Instron tester dated Mar. 12, 2008 (4 pages).
`EP1658055: Experimental Report Breaking strength tests on
`uncalibrated Instron tester dated Dec. 6, 2007 (10 pages).
`EP1658055: IPSearch, Summary of prior art search for EP1658055
`provided by Swiss Intellectual Property Office dated Dec. 3, 2007
`(117 pages).
`EP1658055: Opposition brief filed on Dec. 14, 2007 (14 pages).
`
`EP1658055: Patentee's Response to Opposition dated Oct. 31.
`2008, with English translation (23 pages).
`EP1658055: Third Party Observation dated Feb. 2, 2009 (4 pages).
`EP1658055: Third Party Observation dated Mar. 27, 2009 (3 pages).
`EP1897545: Communicated dated Dec. 20, 2007 from the European
`Patent Office containing the European Search Report (6 pages).
`EP1897545: Response to Office Communication dated May 21,
`2008 (15 pages).
`EP2070538: Annex 1 of the Report: Photos from First Hydration
`Rate (9 pages)—Mar. 5, 2010.
`EP2070538: Communication dated Jun. 25, 2009 from the Euro
`pean Patent Office (4 pages).
`EP2070538: Communication dated May 18, 2009 from the Euro
`pean Patent Office including the European Search Report (3 pages).
`EP2070538: Response to Office Communicated dated Mar. 5, 2010
`(23 pages).
`EP2080514: Communication dated Jun. 15, 2009 from the Euro
`pean Patent Office containing the European Search Report (3
`pages).
`EP2080514: Office Action from EPO dated Jul 14, 2009 (4 pages).
`EP2080514: Response to Office Communicated dated Mar. 19, 2010
`(14 pages).
`EP2082742: Communication dated Jul 9, 2009 from the European
`Patent Office (4 pages).
`EP2082742: Communication dated Jun. 15, 2009 from the Euro
`pean Patent Office containing the European Search Report (3
`pages).
`EP2082742: Response to Office Communication dated Mar. 19.
`2010 (21 pages).
`Fallbe et al. (Eds.), “Rompp Chemie Lexikon.” with English trans
`lation, 9 pages (1992).
`Ando( Lab Paragraph IV Letter, Feb. 7, 2011. Confidential Filed
`Under Seal.
`Watson Paragraph IV Letter, Feb. 7, 2011. Confidential Filed
`Under Seal.
`Teva Paragraph IV Letter, Feb. 9, 2011. Confidential—Filed Under
`Seal.
`Actavis Paragraph IV Letter, Feb. 15, 2011. Confidential Filed
`Under Seal.
`Purdue v. Impax Paragraph IV Letter, Feb. 23, 2011. Confiden
`tial—Filed Under Seal.
`Ranbaxy Paragraph IV Letter, Feb. 24, 2011. Confidential Filed
`Under Seal.
`Ranbaxy Paragraph IV Letter, Mar. 23, 2010. Confidential Filed
`Under Seal.
`Mylan Paragraph IV Letter, Apr. 1, 2010. Confidential Filed
`Under Seal.
`Actavis Paragraph IV Letter, Apr. 8, 2010. Confidential Filed
`Under Seal.
`Ranbaxy Paragraph IV Letter, Apr. 8, 2010. Confidential Filed
`Under Seal.
`Mylan Paragraph IV Letter (U.S. Pat. No. 7,683,072), Apr. 9, 2010.
`Confidential—Filed Under Seal.
`Mylan Paragraph IV Letter (U.S. Pat. No. 7,674,799 and U.S. Pat.
`No. 7,674,800), Apr. 9, 2010. Confidential Filed Under Seal.
`Varam, Inc. Paragraph IV Letter, Jun. 28, 2010. Confidential—
`Filed Under Seal.
`Ranbaxy Paragraph IV Letter (NDA No. 02-2272), Aug. 25, 2011.
`Confidential—Filed Under Seal.
`Purdue Paragraph IV Letter (Amneal Pharmaceuticals), Sep. 28.
`2011. Confidential Filed Under Seal.
`Sandoz Paragraph IV Letter, May 23, 2011 Confidential Filed
`Under Seal.
`Podczeck et al., “Investigations into the tensile failure of doubly
`convex cylindrical tablets under diametral loading using finite
`element methodology.” International Journal of Pharmaceutics 454
`(2013) 412-424.
`Wikipedia Newton (unit) (2014).
`Purdue v. Teva, Trial Decision (Case 04-MD-01603-Shs 568) (# 149
`Jan. 14, 2014).
`Report: Cured v. Heat-Compressed Peo Tablets (Mar. 2010); Sub
`mitted in EP 2 070538 (Application No. 09 156832.9) and other EP
`and foreign applications.
`
`KASHIV1001
`IPR of Patent No. 9,492,392
`
`

`

`US 9,492,392 B2
`Page 6
`
`(56)
`
`References Cited
`
`OTHER PUBLICATIONS
`Choi et ai, “Development of a directly compressible poly(ethylene
`oxide) matrix for the sustained-release of dihydrocodeinebitartrate”
`Drug Dev and Ind. Pharm, 2003, 29(10), 1045-1052.
`Vippagunta et al., “Chrystalline solids'. Advanced Drug Delivery
`Reviews, 2001, 48, pp. 3-26.
`Braga et al., “Crystal polymorphism and multiple crystal forms'
`Struct. Bond, 2009, 132, pp. 25-50.
`Mueller U. “Polymorphism”, Inorganic Structural Chemistry, John
`Wiley and Sons, 1993, pp. 14-15.
`Donnelly, Craig L., “ADHD medications: past and future.” Behav
`ioral Health Management, (May 1, 2002).
`Ciccone Patrick, "Attempted Abuse of Concerta,” Letters to the
`Editor, J. Am. Acad. Child Adolesc. Psychiatry, 41:7, (Jul. 2002).
`Cone, E.J., “Ephemeral profiles of prescription drug and forumla
`tion tampering: Evolving pseudoscience on the Internet,” Drug and
`Alcohol Dependence 83S S31-S39 (2006).
`Jaffe, Steven L., M.D., “Failed Attempts at Intranasal Abuse of
`concerta,’ Letters to the Editor, J. Am. Acad. Child Adolesc,
`Psychiatry, 41:1. (Jan. 2002).
`Bruan, David B. "Poly(Ethylene Oxide).” Published by Union Car
`bide Corporation, at p. 19-20 (1980).
`Griffith, Dorsey, "Potential new ADHD drug creating lots of big
`hopes.” Sacramento Bee (California), (Oct. 30, 2002).
`“Practice Parameter for the Use of Stimulant Medications in the
`Treatment of Children, Adolescents, and Adults,” J. AM. Acad.
`Child Adolesc. Psychiatry, 41:2 Supplement, (Feb. 2002).
`Huang, H., et al., “Preparation of Controlled Release Oral Dosage
`Froms by Low Temperature Melt Extrusion.” American Association
`of Pharmaceutical Scientists, (Nov. 2000), Annual Meeting
`Extracts, Union Carbide Corporation.
`Currie, A.C.. Some Reactions of 14-Hydroxycodeine, J. chemical
`Socy 773 (1960).
`Stewart, A.W., Heterocyclic Division, 16 Ann. Rep. on Progress
`Chemistry 104 (1919).
`Apicella et al., “Poly(ethylene oxide) (PEO) Constant Release
`Monolithic Devices' Polymers in Medicine: Biomedical and Phar
`maceutical Applications, Chapter 3 (1993).
`Harris, Daniel C. Quantitative Chemical Analysis 646-49 (5th ed.
`1999).
`De Jong, Pharmaceutisch Weekblad Scientific Edition, 24-28
`(1987).
`Dow Technical Data, Polyox TM WSR, (Feb. 2003).
`Final Draft Labeling for Concerta Extended Release Tablets, (dated
`Jul. 2000), http://www.accessdata.fda.gov/drugSatfia. Sub.--docs/la
`bel/2000/211-211b1.pdf.
`Handbook of Pharmaceutical Excipients, Arthur H. Kibbe, ed. at
`399 (3rd ed. 2000).
`Handbook of Pharmaceutical Excipients 280, (Ainley Wade & Paul
`J. Wellers eds. 2d. 1994).
`Handbook of Pharmaceutical Excipients 454, 460 (Raymond C.
`Rowe et al. eds., 4th ed. 2003).
`http://www.accessdata.fda.gov/sripts/cder/drugsatflaindex.
`cfm?fuseaction--Search.DrugDetails (accessed Aug. 21, 2013).
`http://www.bluelight.ru/vib/archive/index.php/t-36856.html
`(accessed Apr. 26, 2013).
`http://www.bluelight.ru/vib/archive/index.php/t-39723.html
`(accessed Apr. 26, 2013).
`Ikuo Iijima et al., Studies in the (+)-Morphinan Series, 5, Synthesis
`and Biological Properties of (+)Naloxone, 21 J. Medicinal Chem
`istry 398 (1978).
`Seki, Isao, Studies on the Morphine Alkaloids and Its Related
`Compounds, XV. 17 Chemical & Pharm. Bull, 1549 (1969).
`Letter from Janet Woodcock, M.D., Director, Center for Drug
`Evaluation and Research, FDA to Philip C. Strassburger, Purdue
`Pharma L.P. and Edward B. Mahony, Rhodes Technologies Inc.,
`Responding to Citizen Petition and Petition for Stay of Action(Mar.
`24, 2008).
`
`Chapman, Robert, U.S. Appl. No. 60/651,778, “Process for prepar
`ing oxycodone hydrochloride having less than 25 PPM
`14-hydroxycodeinone” (filed Feb. 10, 2005).
`Skelly et al., Scaleup of Oral Extended-Release Dosage Forms,
`Pharmaceutical Research 10(12) 1800-05 (1993).
`Compilation of Monographs from Physicians' Desk Reference, 54th
`ed (2000).
`McGinity et al., Hot-Melt Extrusion as a Pharmaceutical Process, V.
`4 (2), 25-36 (2001).
`FDA's Guidance for Industry SUPAC-MR: Modified Release Solid
`Oral Dosage Forms, (Sep. 1997).
`Maurer, Peter J. et al., Nitrogen-Bridged Conformationally Con
`strained Etrophine Analogues. Synthesis and Bio